Blackstone to provide up to $750M to fund Moderna’s influenza program

Blackstone (BX) announced a new collaboration with Moderna (MRNA) through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences will provide up to $750M to fund Moderna’s influenza program. This new collaboration continues Blackstone Life Sciences’ work and support for many of the world’s leading and most innovative biopharmaceutical and medical technology companies. Blackstone seeks to provide customized financing solutions for companies across therapeutic areas to support mission critical scientific innovation and advance important products to patients.